DropGenie secures $5 million in Seed+ funding to scale its functional biology platform, enabling broader access to patient-derived cell data for discovery teams.
DropGenie, a private functional biology company, secured $5 million in Seed+ financing, indicating positive growth momentum and validation of its platform.
Montreal-based functional biology firm DropGenie has raised $5 million in Seed+ financing to expand its patient-derived cell discovery platform. The capital injection will accelerate the company's ability to provide on-demand, decision-ready data to drug discovery teams.
DropGenie is a functional biology company that generates decision-ready discovery data using patient-derived cells.
The $5 million in Seed+ financing will be used to bring primary-cell functional data to more discovery teams on an on-demand basis.